A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Stopped early · Phase 3

Conditions studied: Growth Hormone Deficiency

In brief

This study is a multi-center, open-label safety study assessing long-term somavaratan administration.

Key facts

Study ID

NCT03145831

Run by

Versartis Inc.

People needed

21

Starts

2017-03-31

Expected to finish

2017-11-30

Last updated by the study team

2018-03-09

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronological Age ≥ 3.0 years.
• Pre-pubertal status: Absent breast development in girls, testicular volume < 4.0 mL in boys.
• Subjects with GHD (diagnosed according to the current diagnostic guidelines) who are receiving treatment with daily rhGH.
• Normal thyroid function at screening visit in subjects not being treated for hypothyroidism. Subjects requiring thyroxine replacement must be considered adequately treated by the PI and Medical Monitor.
• Normal adrenal function (morning cortisol and/or local stimulation test) at screening visit or within 6 months of the screening visit, in subjects not being treated for adrenal insufficiency. Subjects with adrenal insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before study drug administration.
• Pathology relating to cause of GHD must be stable for at least 6 months prior to screening.
• Willingness to discontinue daily rhGH therapy.
• Legally authorized representatives must be willing and able to give informed consent

You may not qualify if…

• 1. Prior (in the last 12 months) or concomitant treatment with a growth promoting agent other than rhGH [e.g., IGF-I, GH releasing hormone (GHRH), sex steroids (except when used as primer for GH stimulation test), aromatase inhibitors and/or GnRH agonist].
• Current significant disease (e.g., diabetes, cystic fibrosis, renal insufficiency). In all cases of concurrent disease, screening must be approved in writing by the medical monitor.
• Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome (e.g., Russell Silver, Prader Willi, Turner, etc.).
• Birth weight and/or birth length less than 5th percentile for gestational age using local gestational age growth charts.
• Prolonged daily (> 14 days) use of anti-inflammatory doses of oral glucocorticoids.
• Prior history of malignancy. 7. Treatment with an investigational drug in the 30 days prior to screening. 8. Known allergy to constituents of the study drug formulation. 9. Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening.
• Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation, and spina bifida variants.
• Significant abnormality in screening laboratory studies (as assessed by PI and medical monitor).
• Current social conditions which would prevent completion of study activities (e.g., planned family move to a distant location).
• History of pancreatitis or undiagnosed chronic abdominal pain. 14. History of spinal or total body irradiation. 15. Presence of other pituitary hormone deficiencies that are not properly treated.
• Unwillingness to provide consent for participation in all trial activities

Where it is running

• Eric Humphriss — Menlo Park, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.